Cancer Clinical Trial
— CancerPEPOfficial title:
CancerPEP Phase 2 Randomized Trial: Feasibility of a Comprehensive Cancer Patient Empowerment Program Providing Immediate Versus Delayed Stress Reduction Biofeedback Equipment
Verified date | April 2024 |
Source | Nova Scotia Health Authority |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Cancer Patient Empowerment Program is a comprehensive health promotion program aiming to improve the quality of life as well as both physical and mental health in cancer patients and survivors. The program includes daily email communications over 6 months that encourage strength and aerobic exercise, yoga, stress reduction techniques, dietary improvements, and more.
Status | Active, not recruiting |
Enrollment | 104 |
Est. completion date | March 15, 2025 |
Est. primary completion date | February 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: - Age >18. - History of a cancer diagnosis as per the participant's report. - Safe to exercise and do strength training. Participants who have recovered from a minor stroke or heart condition in the past will require approval from their Family Physician or Cardiologist to participate in the study. - Participants with advanced cancer (including cancer spread to bones) will need approval from the Study Physician or their Oncologist to participate. - Existing (or willingness to create) email account and willingness to access email daily. - Ability to follow website links to watch YouTube videos. - Ability to understand and speak English. - Ability to participate in low to moderate levels of physical activity and strength training. - Ability and willingness to fill out an online survey at baseline, and 6, 12 and possibly 24 months, and a weekly compliance survey for the six months of the program. - Deemed to have an expected survival greater than 1 year and expected to be well enough to complete the six-month training Exclusion Criteria: - Patients deemed unfit to participate in low to moderate level exercise e.g., including but not limited to a myocardial infarction or stroke within the last year, without approval from their Family Physician or Cardiologist that they are safe to exercise. - Unable to access the internet and lack of a computer or smartphone to receive emails required for study intervention, or unable to click on a link to successfully watch a YouTube video. - Those with a predicted survival less than 1 year, or not expected to be able to participate in the program for six months. |
Country | Name | City | State |
---|---|---|---|
Canada | QEII Health Sciences Centre | Halifax | Nova Scotia |
Lead Sponsor | Collaborator |
---|---|
Nova Scotia Health Authority | Dalhousie University |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility (accrual, attrition, compliance, and adverse events) | As measured by accrual, attrition, compliance rates, and safety by number of adverse events. | 6 - 24 months | |
Secondary | Mental Health as assessed by the Kessler Kessler Psychological Distress Scale (K10) | A 10 item questionnaire that assesses psychological distress. The scale has a score range of 10-50, with higher scores indicating worse mental health. | 6 - 24 months | |
Secondary | General Health (Physical and Mental) Quality of Life assessed by the 12-item Short Form Health Survey (SF-12) | A 12 item questionnaire. The scale has a score range of 0-100, with higher scores indicating better physical and mental health functioning. | 6 - 24 months | |
Secondary | Health-Related Quality of Life as assessed by the Functional Assessment of Cancer Therapy - General (FACT-G) | A 27 item questionnaire that measures the four domains of HRQOL in cancer patients: Physical, social, emotional, and functional well-being. The scale has a score range of 0-108, with higher scores indicating better quality of life. | 6 - 24 months | |
Secondary | Personality as assessed by the Ten-Item Personality Inventory (TIPI) | A 10 item questionnaire assessing the Big-Five personality dimensions (Extraversion, Agreeableness, Conscientiousness, Emotional Stability, Openness to Experiences). The scale has a score range of 1-14 for each dimension with higher scores indicating a higher level of that personality trait. | 6 - 24 months | |
Secondary | Alcohol Habit assessed by questions from the NIH Alcohol Consumption questionnaire. | Questions assessing alcohol consumption | 6 - 24 months | |
Secondary | Smoking habit assessed by the Global Adult Tobacco Survey 2020 (GATS). | Questions assessing smoking use | 6 - 24 months | |
Secondary | Diet assessed by the Rapid Eating Assessment for Participants (REAP-S). | A 16 item questionnaire assessing diet quality. The scale has a score range of 13-39 with a higher score indicating a higher diet quality. | 6 - 24 months | |
Secondary | Comorbidity level assessed by the modified Charlson Comorbidity Index (CCI) | Each category is scored from 1-6. The higher the score, the more likely the predicted outcome will result in mortality or higher resource use. | 6 - 24 months | |
Secondary | Availability of social support assessed by the MOS Social Support Survey | A 19 item questionnaire that assesses emotional/informational support, positive social interaction, tangible support and affectionate support. Higher item scores reflect a higher level of social support. | 6 - 24 months | |
Secondary | Sleep Quality as assessed by the Pittsburgh Sleep Quality Index (PSQI) | A 19 item questionnaire that assesses sleep quality and disturbances. The scale has a score range of 0-21 with a higher score indicating worse sleep quality. | 6 - 24 months | |
Secondary | Sedentary behaviour measured by the Sedentary Behaviour Questionnaire (SBQ) for Adults. | Two 9 item questionnaires (weekday and weekend) with each item scored to none to 6 hours or more. The total score is the sum of the amount of time and as it increases it indicates higher amount of sedentary behaviour. | 6 - 24 months | |
Secondary | Sexual functioning in women assessed by the 6-item Female Sexual Function Index (FSFI-6). | A 6-item shortened version of the original index. Items are rated on a 5-point Likert scale, ranging from 1 to 5, and the other items are rated on a 6-point Likert scale, ranging from 0 to 5. Total scores range from 2 to 30, with lower scores indicating worse sexual functioning. | 6 - 24 months | |
Secondary | Sexual functioning in men assessed by the Sexual Health Inventory in Men (SHIM). | A 5-item questionnaire with scores ranging from 1-25 and lower scores indicating worse sexual functioning. | 6 - 24 months | |
Secondary | Anxiety severity assessed by the GAD-7. | A 7 item questionnaire with scores ranging from 0-21 higher scores indicating more severe level of anxiety. | 6 - 24 months | |
Secondary | Relationship satisfaction as assessed by the Dyadic Adjustment Scale (DAS-32). | A 32 item questionnaire that measure an individual's perceptions of their relationship with an intimate partner. The scale has a total score range of 1-151 with a higher score indicating better satisfaction. | 6 - 24 months | |
Secondary | Center for Epidemiologic Studies Depression Scale (CES-D). | A 20 item questionnaire with a possible range of scores from zero to 60, with the higher scores indicating the presence of more depressive symptomatology. | 6 - 24 months | |
Secondary | Satisfaction with Life Scale (SWLS). | A 5 item questionnaire that was designed to measure subjective well-being. Scores range from 5-35 with higher scores indicating higher satisfaction with life. | 6 - 24 months | |
Secondary | Brief Illness Perception Questionnaire (IPQ). | A 9 item sale that measures an individual's beliefs, feelings, and cognitive representations of one's illness. | 6 - 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|